Welcome to our dedicated page for Opus Genetics SEC filings (Ticker: IRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Opus Genetics, Inc. (Nasdaq: IRD) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other filings that document material events, financing transactions, and clinical or regulatory milestones. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small-molecule therapies for other ophthalmic disorders, and its filings offer detailed insight into these activities.
Through its Form 8-K filings, the company reports material agreements and financings, such as securities purchase agreements for registered direct offerings of common stock and pre-funded warrants, including the use of proceeds to advance its LCA5 and BEST1 gene therapy clinical programs. These filings may also describe the terms of pre-funded warrants, closing conditions, and related legal opinions. Additional 8-Ks furnish press releases that announce financial results, cash position, and collaboration revenue, providing context on how Opus Genetics funds its research and development operations.
Regulation FD disclosures and other events reported in SEC filings frequently cover clinical and regulatory developments, including positive data from the OPGx-LCA5 Phase 1/2 trial, enrollment updates, and outcomes of FDA interactions such as Regenerative Medicine Advanced Therapy (RMAT) meetings. The company also uses 8-Ks to disclose inducement equity awards granted under its 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, these filings are paired with AI-powered summaries that help explain the key points of each document, from financing structures to trial design details. Users can review Opus Genetics’ quarterly and annual reports when available, as well as current reports and exhibits, to better understand its ophthalmic gene therapy pipeline, collaboration arrangements, and capital structure as described in its official SEC submissions.
Opus Genetics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on April 20, 2026. Investors will elect nine directors, ratify Ernst & Young, LLP as auditor for 2026, and cast an advisory vote on executive compensation.
A key proposal seeks to amend the Restated Certificate of Incorporation to increase authorized common shares from 125 million to 250 million, expanding the company’s capacity for future equity issuance. The proxy also details an independent board with separate Chair and CEO roles, fully independent key committees, and policies such as no poison pill and a prohibition on hedging by directors and officers.
Opus Genetics, Inc. Chief Operating Officer Joseph K. Schachle reported an automatic sale of 3,719 shares of common stock at $5.2501 per share. The company executed this sale to satisfy tax withholding obligations arising from a restricted stock unit vesting event, and it was not a discretionary trade by Schachle. After the transaction, he directly holds 300,781 shares of Opus Genetics common stock.
Opus Genetics, Inc. executive Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic sale of 2,816 shares of common stock at $5.245 per share. The shares were sold by the company to satisfy tax withholding obligations from a restricted stock unit vesting event, and the filing states this was not a discretionary trade. After this transaction, she directly holds 190,312 shares of common stock.
Opus Genetics, Inc. Chief Executive Officer George Magrath reported an automatic sale of 24,438 shares of common stock at a weighted average price of $5.2102 per share. The shares were sold by the company to cover tax withholding obligations arising from a restricted stock unit vesting event and were not a discretionary trade by the executive. Following this tax-related transaction, Magrath directly holds 1,750,855 shares of Opus Genetics common stock.
Opus Genetics, Inc. Chief Scientific & Dev. Officer Jayagopal Ashwath reported an automatic sale of 3,719 shares of common stock at a weighted average price of $5.1213 per share. The shares were sold to cover tax withholding obligations from a restricted stock unit vesting event and were not a discretionary trade. After this transaction, he holds 516,775 shares directly.
Opus Genetics, Inc. is registering up to 7,374,632 shares of Common Stock for resale by the selling stockholders.
Those shares are issuable upon conversion of 7,374,632 shares of Series B Non‑Voting Convertible Preferred Stock and will be convertible following stockholder approval of an increase in authorized Common Stock and subject to each holder’s beneficial ownership limits.
The registration is a resale registration for the selling stockholders; the Company will not receive proceeds from resale. Shares outstanding were 71,149,045 as of March 5, 2026.
Opus Genetics, Inc. is soliciting proxies for its 2026 virtual annual meeting to be held April 20, 2026
The meeting will consider the election of nine director nominees, ratification of Ernst & Young, LLP as auditor, an advisory vote on named executive officer compensation, and a proposal to amend the Restated Certificate of Incorporation to increase authorized Common Stock from 125 million to 250 million. Shares outstanding were 71,149,045 as of March 5, 2026. The Board recommends a vote FOR all proposals and encourages stockholders to vote by mail, phone, or internet prior to the meeting.
Opus Genetics, Inc. outlines a broad ophthalmology pipeline centered on gene therapies for inherited retinal diseases and a small-molecule eye drop franchise. The company’s lead gene therapy, OPGx-LCA5, has RMAT, Rare Pediatric Disease and Orphan designations and showed vision gains in six treated patients, supporting extension of the ongoing trial into an adaptive Phase 1/2/3 study with dosing planned after commercial-grade supply is ready in the second half of 2026.
OPGx-BEST1 is in a Phase 1/2 trial, where the first participant showed a 12-letter visual acuity gain and structural retinal improvement with good tolerability. Additional AAV programs target RHO, RDH12, MERTK, NMNAT1 and CNGB1, including a planned OPGx-MERTK trial in Abu Dhabi.
Beyond gene therapy, Opus’ phentolamine ophthalmic solution 0.75% is FDA‑approved as RYZUMVI for reversal of pharmacologically induced mydriasis and is partnered globally (excluding parts of Asia) with Viatris, which paid a $35 million upfront and a $10 million approval milestone. Multiple Phase 3 trials in presbyopia and dim‑light vision disturbances met primary endpoints, and the FDA has accepted a supplemental NDA for presbyopia with an October 17, 2026 PDUFA date. The company also describes Phase 2b data and a Special Protocol Assessment for oral small molecule APX3330 in diabetic retinopathy, while indicating it is seeking a partner to advance that program.